Examination of large intestine contraction patterns by mosapride citrate for irritable bowel syndrome (IBS, constipation type) using a capsule endoscope

Examination of large intestine contraction patterns by mosapride citrate for irritable bowel syndrome (IBS, constipation type) using a capsule endoscope - The change of symptom of irritable bowel syndrome is correlative with the capsule transit time.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001377

Enrollment

Registered

2008-09-17

Start date

2008-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome (constipation type)

Interventions

Mosapride citrate 15 mg taken once daily in the morning after meal. Administration period is 4 to 5 weeks. Capsule endoscopy conducted before administration and after end of administration period.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with irritable bowel syndrome (IBS, constipation type) in whom the lack of recognizable organic disorders has been confirmed by colonoscopy (CF), and whose blood AST (GOT) and ALT (GPT) are no more than 2 times the upper limit of the facility standard (based on Rome III criteria).

Exclusion criteria

Exclusion criteria: 1) Patients who have taken mosapride citrate or other gastrointestinal function improving drug within 1 week before enrollment in prior treatment. 2) Patients with serious hepatic or renal impairment. 3) Patients taking a gastrointestinal function improving drug other than mosapride citrate concomitantly. 4) Patients with previous gastrointestinal surgery. 5) Patients with long-term use of nonsteroidal antiphlogistic analgetics. 6) Patients undergoing radiation therapy. 7) Patients taking calcium antagonists. 8) Patients taking iron or sucralfate preparations who cannot stop before start of the study. 9) Patients with ulcers, hemorrhage, gastrointestinal stenosis, obstruction, etc. 10) Patients with Crohn's disease. 11) Patients with an embedded electronic medical device such as a cardiac pacemaker. 12) Patients with dysphagia. 13) Patients with serious gastrointestinal diverticular disease. 14) Patients complicated by diabetes. 15) Patients with a history of allergy to mosapride citrate. 16) Patients whom the attending physician judges to be an inappropriate subject.

Design outcomes

Primary

Measure	Time frame
Symptoms of IBS	—

Countries

Japan

Contacts

Public ContactNakamura Masanao

Nagoya University Graduate School of Medicine Department of Gastroenterology

makamura@med.nagoya-u.ac.jp052-744-2172

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026